{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:46:24Z","timestamp":1777776384930,"version":"3.51.4"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Factor XI is a zymogen with an important role in the coagulation cascade. It is activated by FXII, thrombin and or it can be autoactivated. It has a prothrombotic effect after being activated by thrombin, but also through its antifibrinolytic action, stabilizing the formed clot.<\/jats:p>\n                  <jats:p>Hereditary deficiency of FXI causes haemophilia C - a disease manifested by an usually provoked, small to moderate mucosal bleeding. People with severe FXI deficiency have a low risk of thrombotic events. Conversely, increased FXI values have been found to be associated with increased risk of venous thromboembolism and ischemic stroke.<\/jats:p>\n                  <jats:p>Lowering serum FXI levels has become a treatment target for the prevention of thrombotic events. New pharmacological agents - FXI inhibitors - have been investigated in phase II clinical trials, with promising results in terms of efficacy and safety in the prevention of thrombotic events. FXI inhibitors are emerging as new anticoagulant agents with broad indication prospects beyond direct oral anticoagulants and vitamin K antagonists.<\/jats:p>","DOI":"10.2478\/rjim-2023-0034","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T12:51:11Z","timestamp":1703767871000},"page":"91-100","source":"Crossref","is-referenced-by-count":1,"title":["Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives"],"prefix":"10.2478","volume":"62","author":[{"given":"Ana-Maria","family":"Vl\u0103d\u0103reanu","sequence":"first","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy , Department of Hematology, Emergency University Hospital of Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Ro\u015fca","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine and Pharmacy , Department of Functional Sciences, Division of Physiology , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"2026042914162519332_j_rjim-2023-0034_ref_001","doi-asserted-by":"crossref","unstructured":"HSU C., HUTT E., BLOOMFIELD DM., GAILANI D., WEITZ JI. \u2013 \u201cFactor XI inhibitor to uncouple thrombosis from hemostasis: JACC review topic of the week\u201d \u2013 J Am Coll Cardiol 2021, 78: 625-31","DOI":"10.1016\/j.jacc.2021.06.010"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_002","doi-asserted-by":"crossref","unstructured":"EMSLEY J., McEWAN P.A., GAILANI D. \u2013 \u201cStructure and function of Factor XI\u201d \u2013 Blood 2010, 115: 2569-2577","DOI":"10.1182\/blood-2009-09-199182"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_003","doi-asserted-by":"crossref","unstructured":"MOHAMMED BM., MATAFANOV A., IVANOV I., SUN MF., CHENG Q, DICKESON SK. et al \u2013 \u201cAn update on factor XI structure and function\u201d \u2013 Thromb Res 2018, 161: 94-105","DOI":"10.1016\/j.thromres.2017.10.008"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_004","doi-asserted-by":"crossref","unstructured":"PUY C., RIGG R.A., McCARTY O.J.T. \u2013 \u201cThe hemostatic role of Factor XI\u201d \u2013 Thromb Res 2016, 141: S8-S11","DOI":"10.1016\/S0049-3848(16)30354-1"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_005","doi-asserted-by":"crossref","unstructured":"BOUMA BN., MEIJERS JC. \u201cRole of blood coagulation factor XI in downregulation of fibrinolysis\u201d \u2013 Current Opinion in Hematology 2020, 7(5): 266-272","DOI":"10.1097\/00062752-200009000-00002"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_006","doi-asserted-by":"crossref","unstructured":"REITSMA SE., PANG J., RAGHUNATHAN V., SHATZEL JJ., LORENTZ CU., TUCKER EI, et al. \u2013 \u201cRole of platelets in regulating activated coagulation Factor XI activity\u201d \u2013 Am J Physiol Cell Physiol 2021, 320(3): C365-C374","DOI":"10.1152\/ajpcell.00056.2020"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_007","doi-asserted-by":"crossref","unstructured":"DUGA S, SALOMON O. \u2013 \u201cCongenital Factor XI deficiency; an update\u201d \u2013 Sem Thromb Hemost 2013, 39: 621-631","DOI":"10.1055\/s-0033-1353420"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_008","doi-asserted-by":"crossref","unstructured":"LEWANDOWSKA MD, CONNORS J.M. \u2013 \u201cFactor XI deficiency\u201d \u2013 Hematol\/Oncology Clinic 2021, 35(6): 1157-1169","DOI":"10.1016\/j.hoc.2021.07.012"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_009","doi-asserted-by":"crossref","unstructured":"ZANG X., LEWANDOWSKA M., ALDRIGE M. \u2013 \u201cGlobal epidemiology of factor XI deficiency\u201d \u2013 Haemofilia 2023, 29(2): 423-434","DOI":"10.1111\/hae.14687"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_010","doi-asserted-by":"crossref","unstructured":"PREIS M., HIRSCH J., KOTLER A., et al. \u2013 \u201cFactor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events\u201d \u2013 Blood 2017, 129(09): 1210-1215","DOI":"10.1182\/blood-2016-09-742262"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_011","doi-asserted-by":"crossref","unstructured":"SALOMON O., STEINBERG D.M., KOREN-MORAG N., TANNE D., SELIGSOHN U. \u2013 \u201cReduce incidence of ischaemic stroke in patients with severe factor XI deficiency\u201d \u2013 Blood 2008, 111(8): 4113-17","DOI":"10.1182\/blood-2007-10-120139"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_012","doi-asserted-by":"crossref","unstructured":"WHEELER A.P, GAILANI D. \u2013 \u201cWhy factor XI deficiency is a clinical concern\u201d \u2013 Expert Rev Hemat 2016, 9: 629-637","DOI":"10.1080\/17474086.2016.1191944"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_013","doi-asserted-by":"crossref","unstructured":"DE CATERINA R., PRISCO D., EIKELBOOM J.W. \u2013 \u201cFactor XI inhibitors: cardiovascular perspectives\u201d \u2013 Eur Heart J 2023, 44(4): 280-292","DOI":"10.1093\/eurheartj\/ehac464"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_014","doi-asserted-by":"crossref","unstructured":"LING G., KAGDI H., SUBEL B., CHOWDARY P., GOMEZ K. \u2013 \u201cSafety and efficacy of factor XI concentrate use in patients with FXI deficiency\u201d \u2013 Haemophilia 2016, 22: 411","DOI":"10.1111\/hae.12868"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_015","doi-asserted-by":"crossref","unstructured":"MEIJERS JC., TEKELENBURG WL., BOUMA B.N., BERTINA R.M., ROSENDAAL F.R. \u2013 \u201cHigh levels of coagulations Factor XI as a risk factor for venous thrombosis\u201d \u2013 N Engl J Med 2000, 342(10): 696","DOI":"10.1056\/NEJM200003093421004"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_016","doi-asserted-by":"crossref","unstructured":"YANG D.T., FLANDERS M.M., KIM H., RODGERS G.M. \u2013 \u201cElevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events\u201d \u2013 Am J Clin Pathol 2006, 126: 411","DOI":"10.1309\/QC259F09UNMKVP0R"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_017","doi-asserted-by":"crossref","unstructured":"SALOMON O., STEINBERG D.M., ZUCKER M., VARON D., ZIVELIN A., SELIGSOHN U. \u2013 \u201cPatients with severe FXI deficiency have a reduce incidence of deep-vein thrombosis\u201d \u2013 Thromb Haemost 2011, 105: 769-273","DOI":"10.1160\/TH10-05-0307"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_018","doi-asserted-by":"crossref","unstructured":"SHARMAN MOSER S., CHODICK G., NI Y.G., CHALOTHORN D., WANG M.D., SHULDINER A.R., et al. \u2013 \u201cThe association beetween Factor XI deficiency and risk of bleeding, cardiovascular and venous thromboembolic events\u201d \u2013 Thromb Haemost 2022, 122(5): 808-817","DOI":"10.1055\/s-0041-1735971"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_019","doi-asserted-by":"crossref","unstructured":"LOWENBERG E.C., MEIJERS J.C., MONIA B.P., LEVI M.\u2013 \u201cCoagulation factor XI as a novel target for antithrombotic therapy\u201d \u2013 J Thromb Haemost 2010, 8(11): 2349-57","DOI":"10.1111\/j.1538-7836.2010.04031.x"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_020","doi-asserted-by":"crossref","unstructured":"FREDENBURGH J.S., WEITZ J.I. \u2013 \u201cFactor XI as a target for new anticoagulants\u201d \u2013 Hamostaseologie 2021, 41(02): 104-110","DOI":"10.1055\/a-1384-3715"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_021","doi-asserted-by":"crossref","unstructured":"BULLER H.R., BETHUNE C., BHANOT S., GAILANI D., MONIA B.P., RASKOB G.E., et al. \u2013 \u201cFactor XI antisense oligonucleotide for prevention of venous thrombosis\u201d \u2013 N Engl J Med 2015, 372(3): 232-240","DOI":"10.1056\/NEJMoa1405760"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_022","doi-asserted-by":"crossref","unstructured":"HARRINGTON J., PICCINI J.P., ALEXANDER J.H., GRANGER C.B., PATEL M.R.\u2013 \u201cClinical evaluation of Factor XI Inhibitor Drugs: JACC Review Topic of the Week\u201d \u2013 J Am Coll Cardiol 2023, 81(8): 771-779","DOI":"10.1016\/j.jacc.2022.11.057"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_023","doi-asserted-by":"crossref","unstructured":"GRECO A., LAUDANI C., SPAGNOLO M., AGNELLO F., FARO D.C., FINOCCHIARO S., et al. \u2013 \u201cPharmacology and Clinical Development of Factor XI Inhibitors\u201d \u2013 Circulation 2023, 147: 897-913","DOI":"10.1161\/CIRCULATIONAHA.122.062353"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_024","doi-asserted-by":"crossref","unstructured":"VERHAMME P., YI B.A., SEGERS A., SALTER J., BLOOMFIELD D., BULLER H.R., et al. \u2013 \u201cAbelacimab for prevention of venous thromboembolism\u201d \u2013 N Engl J Med 2021, 387: 609-17","DOI":"10.1056\/NEJMoa2105872"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_025","doi-asserted-by":"crossref","unstructured":"WEITZ J.I., STRONY J., AGENO W., GAILANI D., HYLEK E.M., LASSEN M.R., et. al. - \u201cMilvexian for the Prevention of Venous Thromboembolism\u201d - N Engl J Med. 2021 Dec 2;385(23):2161-2172.","DOI":"10.1056\/NEJMoa2113194"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_026","unstructured":"PICCINI J.P., CASO V., CONNOLLY S.J., FOX K.A.A., OLDGREN J., JONES W.S., et. al. - \u201cSafety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study\u201d - Lancet. 2022 Apr 9;399(10333):1383-1390."},{"key":"2026042914162519332_j_rjim-2023-0034_ref_027","doi-asserted-by":"crossref","unstructured":"SHOAMANESH A., MUNDL H., SMITH E.E., MASJUAN J., MILANOV I., HIRANO T., et al. \u2013 for PACIFIC Stroke investigators \u201cFactor XIa inhibition with asundexian after acute noncardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomized, double-blend, placebo-controlled, phase 2b Trial\u201d \u2013 Lancet 2022, 400: 997-1007","DOI":"10.1016\/S0140-6736(22)01588-4"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_028","doi-asserted-by":"crossref","unstructured":"RAO S.V., KIRSCH B., BHATT D.L., BUDAJ A., COPPOLECCHIA R., EIKELBOOM J., et al. \u2013 \u201cA multicenter, phase 2, randomized, placebo-controlled double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes following acute myocardial infarction\u201d \u2013 Circulation 2022, 146: 1196-1206","DOI":"10.1161\/CIR.0000000000001115"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_029","doi-asserted-by":"crossref","unstructured":"GALLI M., LABORANTE R., ORTEGA-PAZ L., FRANCHI F., ROLLINI F., D\u2019AMARIO D., et al. \u2013 \u201cFactor XI inhibitors in early clinical trials: a meta-analysis\u201d \u2013 Throm Haemost 2023, 123: 576-584","DOI":"10.1055\/a-2043-0346"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_030","doi-asserted-by":"crossref","unstructured":"BRAUNWALD E. \u2013 \u201cInhibitors of F XI: game changers of anti-thrombotic therapy?\u201d \u2013 Eur Heart J 2023, 44: 1018-1019","DOI":"10.1093\/eurheartj\/ehac524"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_031","doi-asserted-by":"crossref","unstructured":"WANG TF., KHORANA AA., AGNELLI G., BLOOMFIELD D., BONACA MP., BULLER HR., et al. \u2013 \u201cTreatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction\u201d \u2013 Oncologist. 2023 Jul 5;28(7):555-564.","DOI":"10.1093\/oncolo\/oyad116"},{"key":"2026042914162519332_j_rjim-2023-0034_ref_032","unstructured":"https:\/\/www.bayer.com\/media\/en-us\/oceanic-af-study-stopped-early-due-to-lack-of-efficacy\/ (date of accession: 15.12.2023)."}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/rjim-2023-0034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:23:29Z","timestamp":1777487009000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/rjim-2023-0034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,28]]},"published-print":{"date-parts":[[2024,6,1]]}},"alternative-id":["10.2478\/rjim-2023-0034"],"URL":"https:\/\/doi.org\/10.2478\/rjim-2023-0034","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}